Mannkind Corp (MNKD) 7.00 $MNKD
Shares of MNKD Up 13.2% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Feb 13, 9:55AM CST
SmarTrend identified an Uptrend for MannKind (NASDAQ:MNKD) on October 30th, 2014 at $6.05. In approximately 4 months, MannKind has returned 13.22% as of today's recent price of $6.85.
MNKD: 7.00 (+0.02)
Biotech Stock Mailbag: MannKind, Mast Therapeutics, Bluebird
at The Street - Fri Feb 13, 5:00AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
BLUE: 90.70 (+0.93), MSTX: 0.47 (+0.01), MNKD: 7.00 (+0.02)
Technical Roundup on Biotech Equities - Gilead Sciences, MannKind, ImmunoGen, Dyax, and Pharmacyclics
PR Newswire - Thu Feb 12, 7:45AM CST
Editor Note: For more information about this release, please scroll to bottom.
PCYC: 163.28 (+0.23), GILD: 101.90 (+1.10), IMGN: 7.19 (unch), MNKD: 7.00 (+0.02), DYAX: 15.00 (-0.16)
Short Sellers Eye Genetic Tech
Interactive Brokers - Seeking Alpha - Tue Feb 10, 1:58PM CST
Following the recent increase in its share price, Genetic Tech Ltd. (NASDAQ: GENE ) was a highly sought-after short-borrow request. Limited availability pushed the cost to borrow up substantially while demand remains strong. Shares in GENE spiked...
AMBA: 50.71 (-4.46), GPRO: 45.27 (-0.02), SHAK: 40.69 (+0.04), DDD: 32.81 (+0.40), BBEP: 7.85 (+0.32), SN: 15.21 (-0.12), YOD: 2.22 (+0.04), MNKD: 7.00 (+0.02), MCP: 0.97 (+0.04), GENE: 8.04 (+1.90), BTU: 7.65 (+0.46), IMRS: 1.04 (-0.03), PSTR: 4.63 (+0.14), LINE: 12.94 (+0.40)
MannKind Investors: Don't Screw Up The Afrezza Launch
Psycho Analyst - at Seeking Alpha - Tue Feb 10, 9:50AM CST
MNKD: 7.00 (+0.02), SNY: 49.42 (+0.82)
MannKind (MNKD) Looks Good: Stock Adds 7.8% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 8:25AM CST
MannKind (MNKD) was a big mover last session, with shares rising nearly 8% on the day.
MNKD: 7.00 (+0.02), AFFX: 11.45 (+0.02)
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 4:37PM CST
COUP: 11.06 (-0.07), URBN: 38.47 (+0.27), AMKR: 8.90 (-0.02), CSC: 66.10 (+1.60), CNCO: 7.70 (-0.10), ALSN: 31.88 (+0.24), YDLE: 13.07 (+1.14), MNKD: 7.00 (+0.02), ARO: 3.63 (+0.04), SYK: 94.51 (+1.14)
Why MannKind Corporation's Shares Rocketed Higher Today
Todd Campbell, The Motley Fool - Motley Fool - Mon Feb 09, 4:04PM CST
What: A week after partner Sanofi announced the commercial launch of MannKind Corporation 's inhaled insulin Afrezza, MannKind's shares surged by nearly 10% at one point earlier today before closing with a gain of just under 8%. Source:...
SNY: 49.42 (+0.82), MNKD: 7.00 (+0.02)
Seeking Alpha's Biotech Weekly: Questioning Gilead, MannKind To Market, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 06, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
SGYP: 2.98 (unch), BLUE: 90.70 (+0.93), ZIOP: 9.64 (-0.35), MYGN: 34.03 (+0.40), PSTI: 2.91 (+0.01), PFE: 34.64 (-0.23), XON: 39.30 (+1.05), TKMR: 21.45 (-0.22), ASPX: 65.76 (+2.76), MNKD: 7.00 (+0.02), HSP: 87.35 (unch), ZTS: 45.46 (-0.33), ANTM: 141.05 (-0.95), WMGI: 25.68 (+0.17), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), THOR: 40.01 (+0.54), TEVA: 56.77 (-0.58), ABBV: 58.05 (+1.00), SNY: 49.42 (+0.82), ARNA: 4.55 (+0.02)
Uptrend Call Working As MannKind Stock Rises 17.6% (MNKD)
Comtex SmarTrend(R) - Fri Feb 06, 9:27AM CST
SmarTrend identified an Uptrend for MannKind (NASDAQ:MNKD) on October 30th, 2014 at $6.05. In approximately 3 months, MannKind has returned 17.60% as of today's recent price of $7.11.
MNKD: 7.00 (+0.02)
Inhaled Insulin Now Available in the U.S. (Again)
Brian Orelli, The Motley Fool - Motley Fool - Fri Feb 06, 8:59AM CST
Diabetics looking to avoid some needle pricks have a new option with Sanofi and MannKind 's Afrezza, which is finally available in pharmacies. It's been a long time coming for the drug-device combination. First rejected by the FDA five years...
PFE: 34.64 (-0.23), SNY: 49.42 (+0.82), MNKD: 7.00 (+0.02)
What MannKind Investors Can Learn From The Sanofi Conference Call
Psycho Analyst - at Seeking Alpha - Thu Feb 05, 1:37PM CST
NVO: 43.76 (+0.61), MNKD: 7.00 (+0.02), SNY: 49.42 (+0.82)
Why MannKind Corporation Vaulted 22% Higher in January
Sean Williams, The Motley Fool - Motley Fool - Thu Feb 05, 6:03AM CST
What: Shares of MannKind , a biopharmaceutical company primarily focused on developing therapies to treat diabetes, vaulted higher by 22% in January per, S&P Capital IQ , after announcing the receipt of a milestone payment from partner ...
SNY: 49.42 (+0.82), MNKD: 7.00 (+0.02)
Could MannKind's U.S. Traction Result In A Short Squeeze?
Orange Peel Investments - at Seeking Alpha - Wed Feb 04, 7:59AM CST
MNKD: 7.00 (+0.02)
My Well-Valued Growth Portfolio Beats The S&P 500 For January
Psycho Analyst - at Seeking Alpha - Wed Feb 04, 6:46AM CST
ODFL: 76.25 (+0.96), ESRX: 84.90 (+0.40), THO: 59.19 (-0.44), SWKS: 81.85 (-0.57), LGIH: 13.38 (-0.07), LKQ: 27.22 (+0.10), DG: 68.82 (+1.23), SNY: 49.42 (+0.82), MNKD: 7.00 (+0.02), PCLN: 1,103.37 (+11.42), LUV: 43.30 (-0.20)
Sanofi, Mannkind launch inhaled insulin called Afrezza
By LINDA A. JOHNSON - AP - Tue Feb 03, 4:42PM CST
TRENTON, N.J. (AP) — Hoping to appeal to millions of needle-phobic Americans with diabetes, drugmakers Sanofi and Mannkind have just launched Afrezza, an insulin that's inhaled, rather than injected.
PFE: 34.64 (-0.23), MNKD: 7.00 (+0.02)
MannKind: Great Afrezza Word Of Mouth, But Prescriptions Won't Soar Right Away
Psycho Analyst - at Seeking Alpha - Tue Feb 03, 2:52PM CST
MNKD: 7.00 (+0.02), SNY: 49.42 (+0.82)
Sanofi and MannKind Announce Afrezza®, the Only Inhaled Insulin, Now Available in the U.S.
PR Newswire - Tue Feb 03, 6:00AM CST
Sanofi and MannKind Corporation announced today that Afrezza® (insulin human) Inhalation Powder, the only inhaled insulin, is now available by prescription in U.S. retail pharmacies nationwide. Afrezza is approved by the U.S. Food and Drug Administration to control high blood sugar in adults with type 1 and type 2 diabetes.
SAN: 7.18 (+0.13), MNKD: 7.00 (+0.02), SNY: 49.42 (+0.82)
Sanofi launches inhaled insulin in U.S.
Seeking Alpha - at Seeking Alpha - Tue Feb 03, 5:58AM CST
MNKD: 7.00 (+0.02), SNY: 49.42 (+0.82)
Seeking Alpha's Biotech Weekly: Intercept Pops, Provenge's Prince Valeant, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Jan 30, 3:00PM CST
BCRX: 10.06 (-0.09), ACT: 285.37 (+3.71), VRX: 167.00 (-0.50), PCYC: 163.28 (+0.23), ZSPH: 46.77 (+3.42), RMTI: 11.17 (+0.15), BCLI: 3.86 (-0.02), SIEN: 15.90 (+0.38), JNJ: 99.62 (+1.18), ECYT: 5.26 (-0.02), SNY: 49.42 (+0.82), LENS: 6.00 (-0.67), REGN: 402.40 (+0.66), SYK: 94.51 (+1.14), PFE: 34.64 (-0.23), SLXP: 152.35 (+3.17), AMGN: 153.48 (+0.30), APPY: 0.45 (-0.01), MNKD: 7.00 (+0.02), CELG: 115.88 (+0.16), ISRG: 510.73 (+3.02), GILD: 101.90 (+1.10), ANIP: 62.69 (-0.43), MRK: 58.81 (-0.07), ALXN: 182.29 (+6.02), CCXI: 7.85 (+0.04), ICPT: 209.12 (+7.12), AEZS: 0.53 (unch), ATRS: 2.45 (+0.05), NASH: 31.48 (+0.01)
Shares of MNKD Up 13.2% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Feb 13, 9:55AM CST
SmarTrend identified an Uptrend for MannKind (NASDAQ:MNKD) on October 30th, 2014 at $6.05. In approximately 4 months, MannKind has returned 13.22% as of today's recent price of $6.85.
MNKD: 7.00 (+0.02)
Biotech Stock Mailbag: MannKind, Mast Therapeutics, Bluebird
at The Street - Fri Feb 13, 5:00AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
BLUE: 90.70 (+0.93), MSTX: 0.47 (+0.01), MNKD: 7.00 (+0.02)
Technical Roundup on Biotech Equities - Gilead Sciences, MannKind, ImmunoGen, Dyax, and Pharmacyclics
PR Newswire - Thu Feb 12, 7:45AM CST
Editor Note: For more information about this release, please scroll to bottom.
PCYC: 163.28 (+0.23), GILD: 101.90 (+1.10), IMGN: 7.19 (unch), MNKD: 7.00 (+0.02), DYAX: 15.00 (-0.16)
Short Sellers Eye Genetic Tech
Interactive Brokers - Seeking Alpha - Tue Feb 10, 1:58PM CST
Following the recent increase in its share price, Genetic Tech Ltd. (NASDAQ: GENE ) was a highly sought-after short-borrow request. Limited availability pushed the cost to borrow up substantially while demand remains strong. Shares in GENE spiked...
AMBA: 50.71 (-4.46), GPRO: 45.27 (-0.02), SHAK: 40.69 (+0.04), DDD: 32.81 (+0.40), BBEP: 7.85 (+0.32), SN: 15.21 (-0.12), YOD: 2.22 (+0.04), MNKD: 7.00 (+0.02), MCP: 0.97 (+0.04), GENE: 8.04 (+1.90), BTU: 7.65 (+0.46), IMRS: 1.04 (-0.03), PSTR: 4.63 (+0.14), LINE: 12.94 (+0.40)
MannKind Investors: Don't Screw Up The Afrezza Launch
Psycho Analyst - at Seeking Alpha - Tue Feb 10, 9:50AM CST
MNKD: 7.00 (+0.02), SNY: 49.42 (+0.82)
MannKind (MNKD) Looks Good: Stock Adds 7.8% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 8:25AM CST
MannKind (MNKD) was a big mover last session, with shares rising nearly 8% on the day.
MNKD: 7.00 (+0.02), AFFX: 11.45 (+0.02)
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 4:37PM CST
COUP: 11.06 (-0.07), URBN: 38.47 (+0.27), AMKR: 8.90 (-0.02), CSC: 66.10 (+1.60), CNCO: 7.70 (-0.10), ALSN: 31.88 (+0.24), YDLE: 13.07 (+1.14), MNKD: 7.00 (+0.02), ARO: 3.63 (+0.04), SYK: 94.51 (+1.14)
Why MannKind Corporation's Shares Rocketed Higher Today
Todd Campbell, The Motley Fool - Motley Fool - Mon Feb 09, 4:04PM CST
What: A week after partner Sanofi announced the commercial launch of MannKind Corporation 's inhaled insulin Afrezza, MannKind's shares surged by nearly 10% at one point earlier today before closing with a gain of just under 8%. Source:...
SNY: 49.42 (+0.82), MNKD: 7.00 (+0.02)
Seeking Alpha's Biotech Weekly: Questioning Gilead, MannKind To Market, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 06, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
SGYP: 2.98 (unch), BLUE: 90.70 (+0.93), ZIOP: 9.64 (-0.35), MYGN: 34.03 (+0.40), PSTI: 2.91 (+0.01), PFE: 34.64 (-0.23), XON: 39.30 (+1.05), TKMR: 21.45 (-0.22), ASPX: 65.76 (+2.76), MNKD: 7.00 (+0.02), HSP: 87.35 (unch), ZTS: 45.46 (-0.33), ANTM: 141.05 (-0.95), WMGI: 25.68 (+0.17), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), THOR: 40.01 (+0.54), TEVA: 56.77 (-0.58), ABBV: 58.05 (+1.00), SNY: 49.42 (+0.82), ARNA: 4.55 (+0.02)
Uptrend Call Working As MannKind Stock Rises 17.6% (MNKD)
Comtex SmarTrend(R) - Fri Feb 06, 9:27AM CST
SmarTrend identified an Uptrend for MannKind (NASDAQ:MNKD) on October 30th, 2014 at $6.05. In approximately 3 months, MannKind has returned 17.60% as of today's recent price of $7.11.
MNKD: 7.00 (+0.02)
Inhaled Insulin Now Available in the U.S. (Again)
Brian Orelli, The Motley Fool - Motley Fool - Fri Feb 06, 8:59AM CST
Diabetics looking to avoid some needle pricks have a new option with Sanofi and MannKind 's Afrezza, which is finally available in pharmacies. It's been a long time coming for the drug-device combination. First rejected by the FDA five years...
PFE: 34.64 (-0.23), SNY: 49.42 (+0.82), MNKD: 7.00 (+0.02)
What MannKind Investors Can Learn From The Sanofi Conference Call
Psycho Analyst - at Seeking Alpha - Thu Feb 05, 1:37PM CST
NVO: 43.76 (+0.61), MNKD: 7.00 (+0.02), SNY: 49.42 (+0.82)
Why MannKind Corporation Vaulted 22% Higher in January
Sean Williams, The Motley Fool - Motley Fool - Thu Feb 05, 6:03AM CST
What: Shares of MannKind , a biopharmaceutical company primarily focused on developing therapies to treat diabetes, vaulted higher by 22% in January per, S&P Capital IQ , after announcing the receipt of a milestone payment from partner ...
SNY: 49.42 (+0.82), MNKD: 7.00 (+0.02)
Could MannKind's U.S. Traction Result In A Short Squeeze?
Orange Peel Investments - at Seeking Alpha - Wed Feb 04, 7:59AM CST
MNKD: 7.00 (+0.02)
My Well-Valued Growth Portfolio Beats The S&P 500 For January
Psycho Analyst - at Seeking Alpha - Wed Feb 04, 6:46AM CST
ODFL: 76.25 (+0.96), ESRX: 84.90 (+0.40), THO: 59.19 (-0.44), SWKS: 81.85 (-0.57), LGIH: 13.38 (-0.07), LKQ: 27.22 (+0.10), DG: 68.82 (+1.23), SNY: 49.42 (+0.82), MNKD: 7.00 (+0.02), PCLN: 1,103.37 (+11.42), LUV: 43.30 (-0.20)
Sanofi, Mannkind launch inhaled insulin called Afrezza
By LINDA A. JOHNSON - AP - Tue Feb 03, 4:42PM CST
TRENTON, N.J. (AP) — Hoping to appeal to millions of needle-phobic Americans with diabetes, drugmakers Sanofi and Mannkind have just launched Afrezza, an insulin that's inhaled, rather than injected.
PFE: 34.64 (-0.23), MNKD: 7.00 (+0.02)
MannKind: Great Afrezza Word Of Mouth, But Prescriptions Won't Soar Right Away
Psycho Analyst - at Seeking Alpha - Tue Feb 03, 2:52PM CST
MNKD: 7.00 (+0.02), SNY: 49.42 (+0.82)
Sanofi and MannKind Announce Afrezza®, the Only Inhaled Insulin, Now Available in the U.S.
PR Newswire - Tue Feb 03, 6:00AM CST
Sanofi and MannKind Corporation announced today that Afrezza® (insulin human) Inhalation Powder, the only inhaled insulin, is now available by prescription in U.S. retail pharmacies nationwide. Afrezza is approved by the U.S. Food and Drug Administration to control high blood sugar in adults with type 1 and type 2 diabetes.
SAN: 7.18 (+0.13), MNKD: 7.00 (+0.02), SNY: 49.42 (+0.82)
Sanofi launches inhaled insulin in U.S.
Seeking Alpha - at Seeking Alpha - Tue Feb 03, 5:58AM CST
MNKD: 7.00 (+0.02), SNY: 49.42 (+0.82)
Seeking Alpha's Biotech Weekly: Intercept Pops, Provenge's Prince Valeant, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Jan 30, 3:00PM CST
BCRX: 10.06 (-0.09), ACT: 285.37 (+3.71), VRX: 167.00 (-0.50), PCYC: 163.28 (+0.23), ZSPH: 46.77 (+3.42), RMTI: 11.17 (+0.15), BCLI: 3.86 (-0.02), SIEN: 15.90 (+0.38), JNJ: 99.62 (+1.18), ECYT: 5.26 (-0.02), SNY: 49.42 (+0.82), LENS: 6.00 (-0.67), REGN: 402.40 (+0.66), SYK: 94.51 (+1.14), PFE: 34.64 (-0.23), SLXP: 152.35 (+3.17), AMGN: 153.48 (+0.30), APPY: 0.45 (-0.01), MNKD: 7.00 (+0.02), CELG: 115.88 (+0.16), ISRG: 510.73 (+3.02), GILD: 101.90 (+1.10), ANIP: 62.69 (-0.43), MRK: 58.81 (-0.07), ALXN: 182.29 (+6.02), CCXI: 7.85 (+0.04), ICPT: 209.12 (+7.12), AEZS: 0.53 (unch), ATRS: 2.45 (+0.05), NASH: 31.48 (+0.01)
